- $10.02bn
- $9.97bn
- $4.89bn
- 96
- 54
- 66
- 84
Annual income statement for Amdocs, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,087 | 4,169 | 4,289 | 4,577 | 4,888 |
| Cost of Revenue | |||||
| Gross Profit | 1,434 | 1,413 | 1,478 | 1,619 | 1,728 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3,517 | 3,574 | 3,464 | 3,902 | 4,234 |
| Operating Profit | 570 | 595 | 825 | 675 | 654 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 568 | 583 | 814 | 648 | 636 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 479 | 498 | 688 | 550 | 543 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 479 | 498 | 688 | 550 | 541 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 476 | 494 | 681 | 542 | 532 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.47 | 3.71 | 3.83 | 4.37 | 5 |
| Dividends per Share |